Status:

COMPLETED

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Lead Sponsor:

Acrotech Biopharma Inc.

Conditions:

Peripheral T-cell Lymphoma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for belinostat when combined with CHOP regimen and establish the recommended belinostat dose for the Phase 3 study.

Detailed Description

This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose (MTD) of belinostat when administered in combination with CHOP.

Eligibility Criteria

Inclusion

  • Age 18 years or above
  • Life Expectancy \> 3 months
  • Histologically confirmed diagnosis of PTCL
  • Patients with transformed CTCL eligible for CHOP regimen
  • Measurable disease based on Cheson 2007 criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status \< 2

Exclusion

  • Known active Hepatitis B/ Hepatitis C/ HIV infection
  • Known, uncontrolled CNS metastases or primary CNS lymphoma
  • Deep vein thrombosis diagnosed within 3 months
  • Ongoing treatment for pre-existing cardiovascular disease
  • Neuropathy Grade 3 or more
  • Previous extensive radiotherapy except limited field RT for locally advanced nasal NK PTCL or for pain palliation
  • Prior therapy with severely myelotoxic regimens, including autologous and allogenic stem cell transplantation
  • Prior therapy with HDAC inhibitors (except for CTCL)
  • Inadequate hematological, hepatic, or renal function

Key Trial Info

Start Date :

May 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2016

Estimated Enrollment :

23 Patients enrolled

Trial Details

Trial ID

NCT01839097

Start Date

May 1 2013

End Date

January 1 2016

Last Update

January 3 2020

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Yale University

New Haven, Connecticut, United States, 06511

2

Northeast Georgia Cancer Care, LLC

Athens, Georgia, United States, 30607

3

Mayo Clinic

Rochester, Minnesota, United States, 55905

4

Washington University School of Medicine

St Louis, Missouri, United States, 63110